AFTER decades of investigative frustration, it now appears that the viruses causing both type A and B hepatitis have been identified, that clear-cut serologic distinctions between these infectious agents have been demonstrated, and that a practical basis for a type B hepatitis vaccine has been established. These events have derived from the explosive proliferation of hepatitis research that followed the first description of the Australia antigen in 1965 by Blumberg et al.1 This commentary will not deal with the many important early discoveries in this area that have been extensively reviewed,2,3 but will focus on more recent findings that provide an experimental framework for our emerging concept of the agents responsible for viral hepatitis.
The Dane Particle
In addition to its clinical association with viral hepatitis, the Australia antigen, hereafter referred to as the hepatitis B surface antigen (HBsAg), became a candidate for the elusive type
Alter HJ, Holland PV, Purcell RH. Viral Hepatitis: Light at the End of the Tunnel. JAMA. 1974;229(3):293–294. doi:10.1001/jama.1974.03230410017014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: